Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf. 2006 Dec 1;15(12):861-72.
McCrink L, Beard SM, Le T. The relationship between health-related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A41.
McCrink L, Beard S, Le TK. The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP). Value Health. 2006 May 1;9(3):A41.
Evans C, Katz N, Simon L, Bombardier C, West C, Robbins J, Copley-Merriman K, Coombs J. Development and preliminary validation of a responder index for patients with chronic low back pain. J Pain. 2006 Apr;7(4 (Supplement)):S84. doi: 10.1016/j.jpain.2006.01.341
Williams VSL, Smith M, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage. 2006 Jan 1;31(1):48-57.
Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006 Jan 1;17(1):104-7.
Williams VS, Smith MY, Fehnel SE. The validity and utility of bpi interference measures addressing the impact of pain. Poster presented at the Annual International Society for Quality of Life Research (ISOQOL) Conference; November 2003.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. Safety profile of smell and taste disorders in patients treated with cox-2 specific inhibitors and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.